The Opinion article from Gabriel Ichim and Stephen W. G. Tait, 'A fate worse than death: apoptosis as an oncogenic process' (Nat. Rev. Cancer 16, 539–548; 2016)1, highlights intrinsic mechanisms of failure of commonly used cancer therapies that are heavily dependent on apoptosis. Homeostatic mechanisms are triggered by the presence of dying cells within tissues, favouring the survival of residual tumoural cells in the tumour microenvironment2. Understanding these homeostatic mechanisms will provide actionable targets to enhance the effectiveness of therapeutic strategies used in the clinic.
The presence of apoptotic cells with subtumorigenic numbers of mouse melanoma cells promoted tumour engraftment and growth, in a mechanism dependent on the recruitment of inflammatory cells3. In a separate study, it was shown that clearance of dying cells by tumour macrophages shifts them towards the pro-tumorigenic M2 phenotype by mechanisms involving the receptor for the lipid mediator platelet-activating factor (PAF), a member of the 1-alkyl,2-acylglycerophosphocholine subclass of lipids4.
Lipid mediators are generated in the tumour microenvironment and can modulate tumour growth. Prostaglandin E2 (PGE2) is among the most studied molecular effectors of tumour repopulation following chemotherapy5. PGE2 is derived from the metabolism of membrane phospholipids, through the action of phospholipase A2 (PLA2). Both Ca2+-dependent PLA2 (cPLA2) and Ca2+-independent PLA2 (iPLA2; also known as PLA2G6)6 cleave phosphatidylcholine into arachidonic acid and lysophosphatidylcholine (Fig. 1). Although arachidonic acid can be enzymatically converted into prostanoids, including PGE2, lysophosphatidylcholine is converted into PAF through the action of lysophosphatidylcholine acyltransferases (LPCAT1, LPCAT2, LPCAT3 and LPCAT4)7. Therefore, in situations in which PGE2 is produced, depending on the levels of LPCAT expression, PAF is also produced. In a positive feedback loop, through the activation of its receptor (PAFR), PAF induces either activation of PLA2 (Ref. 8) or induction of cyclooxygenase 2 (COX2) expression9,10, leading to the further release of PGE2. The contribution of PAFR-dependent signalling in tumour repopulation was also demonstrated in its response to chemotherapy and radiotherapy. PAF protects tumour cells from drug-induced cell death, and the administration of PAFR antagonists blocks its protective effect11,12,13
Radiation therapy is among the most potent inducers of PAFR ligands through the oxidation of phospholipids14, whose formation is independent of LPCAT. Regardless of their origin, however, PAFR ligands favour PGE2 production. Experimental radiation therapy was more effective in tumour-engrafted PAFR-knockout mice, as compared with wild type, owing to decreased tumour repopulation in animals devoid of PAFR signalling. Moreover, PAFR ligands induce tissue remodelling and angiogenic cytokine production, through macrophage polarization towards the M2 phenotype. The accumulating evidence for the involvement of PAFR-dependent signalling in the survival response of tumours to chemo- and radiotherapy supports the concept that PAFR antagonists could be used for adjuvant cancer therapy. Several antagonists have been developed in the past, but none has yet been tested for clinical use in cancer. PAFR antagonists are likely to complement strategies that target tumour-associated macrophages (colony-stimulating factor 1 receptor (CSF1R) antagonists) and PGE2 (COX2 inhibitors), which, together, will improve the efficacy of apoptogenic therapies.
There is a reply to this Correspondence by Ichim, G. & Tait, S. W. G. Nat. Rev. Cancer http://dx.doi.org/10.1038/nrc.2017.16 (2017)
References
Ichim, G. & Tait, S. W. G. A fate worse than death: apoptosis as an oncogenic process. Nat. Rev. Cancer 16, 539–548 (2016).
Huang, Q. et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 17, 860–866 (2011).
Correa, M. et al. Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. Int. J. Cancer 114, 356–363 (2005).
Ferracini, M., Rios, F. J. O., Pecenin, M. & Jancar, S. Clearance of apoptotic cells by macrophages induces regulatory phenotype and involves stimulation of CD36 and PAFR receptor. Mediators Inflamm. 2013, 950273 (2013).
Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209–213 (2015).
McHowat, J. et al. Platelet-activating factor and metastasis: calcium-independent phospholipase A2β-deficiency protects against breast cancer metastasis to the lung. Am. J. Physiol. Cell Physiol. 300, C825–C832 (2011).
Murakami, M. & Kudo, I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 43, 3–35 (2004).
Oestvang, J., Anthonsen, M. W. & Johansen, B. LysoPC and PAF trigger arachidonic acid release by divergent signaling mechanisms in monocytes. J. Lipids 2011, 532145 (2011).
Glaser, K. B., Asmis, R. & Dennis, E. A. PAF receptor mediated PGE2 production in LPS primed P388D1 macrophage-like cells. Adv Prostaglandin Thromboxane Leukot Res. 21A, 249–255 (1991).
Ishizuka, E. K., Filgueiras, L. R., Rios, F. J., Serezani, C. H. & Jancar, S. PAFR activation of NF-κB p65 or p105 precursor dictates pro- and anti-inflammatory responses during TLR activation in murine macrophages. Sci. Rep. 6, 16 (2092).
Onuchic, A. C. et al. Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma. Mediators Inflamm. 2012, 175408 (2012).
Sahu, R. P. et al. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 74, 7069–7078 (2014).
Sahu, R. P., Ferracini, M. & Travers, J. B. Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists. Mediators Inflamm. 2015, 820543 (2015).
Sahu, R. P. et al. Radiation therapy generates platelet-activating factor agonists. Oncotarget 7, 20788–20800 (2016).
Acknowledgements
Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2013/15719-0 and 2015/22814-5).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chammas, R., de Sousa Andrade, L. & Jancar, S. Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy. Nat Rev Cancer 17, 253 (2017). https://doi.org/10.1038/nrc.2017.15
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc.2017.15
This article is cited by
-
PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury
Nature Chemical Biology (2024)
-
A matter of life and death: stem cell survival in tissue regeneration and tumour formation
Nature Reviews Cancer (2018)
-
Cancer therapy-induced PAFR ligand expression: any role for caspase activity?
Nature Reviews Cancer (2017)